NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

Don't have an account? Register

Photo

RCSI University of Medicine and Health Sciences

By Mindo - 02nd Nov 2020

Clinician researchers at RCSI University of Medicine and Health Sciences have developed, for the first time, a score that can accurately predict which patients will develop a severe form of COVID-19. The study was published in The Lancet's translational research journal EBioMedicine this month. The measurement, called the Dublin-Boston score, is designed to enable clinicians to make more informed decisions when identifying patients who may benefit from therapies, such as steroids, and admission to intensive care units. Pictured (l-r) is RCSI Professor of Medicine Gerry McElvaney, the study’s senior author with co-author, RCSI Professor of Anaesthesia and Critical Care, Ger Curley. Picture credit: Ray Lohan/ RCSI

Clinician researchers at RCSI University of Medicine and Health Sciences have developed, for the first time, a score that can accurately predict which patients will develop a severe form of Covid-19. The study was published in The Lancet’s translational research journal EBioMedicine last month. The measurement, called the Dublin-Boston score, is designed to enable clinicians to make more informed decisions when identifying patients who may benefit from therapies, such as steroids, and admission to intensive care units.

Pictured L-R are: RCSI Professor of Medicine Gerry McElvaney, the study’s senior author, with co-author, RCSI Professor of Anaesthesia and Critical Care Ger Curley